KYPROLIS (carfilzomib) for Refractory Multiple Myeloma - Cancer Therapy Advisor

KYPROLIS (carfilzomib) for Refractory Multiple Myeloma

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for KYROLIS (carfilzomib), indicated for refractory multiple myeloma.
Table of Contents
Slide 3: Indication, Dosage, and Administration
Slide 11: Use in Specific Populations
Slide 13: Clinical Pharmacology
Slide 17: Warnings and Precautions
Slide 20: Clinical Safety and Efficacy
Slide 26: Drug Storage and Supply
Slide 28: References

Next hm-slideshow in Slides